Bardet Biedl Syndrome

Not only what but also how matters?



Narjess Boutalbi, Nihad Selim, Mohamed Said Nait Abdallah, Nadira Bouchair | Clinique pédiatrique sainte Thérèse, CHU Annaba Narjess.boutalbi@gmail.com

Introduction

- Bardet-Biedl syndrome (BBS) is a multiorgan genetic disease which is a part of ciliopathies. The French National Authority of Health (HAS) published in March 2019 a new National Diagnostic and Care guideline for Bardet Biedl syndrome. However, in practice, we faced many difficulties in the screening and the multidisciplinary care of BBS complications.
- We report our experience with siblings composed of an eight-year-old boy and an 18-month-old girl suffering from BBS. Our objective is to manage obesity, hypogonadism, vision disorders, intellectual disability, and behavioral disorders.
- While the SBB clinical diagnosis seems well defined, the genetic determinism of BBS remains complex, especially that there is a need for an early diagnosis to guide the patient and overcome medical and social problems.

Observation

We report the case of a sibling resulting from a consanguineous marriage with an 8-year-old boy presenting:

- Weight: 52 kg, height: 126 cm, BMI: 33 = obesity (Fig 1.A)
- Syndactyly at both feet (Fig 1.B)
- Hypogonadism, with a micropenis (Fig 1.C)
- Dvelopmental delay: acquisition of walking until the age of 3 years, very limited vocabulary, learning disabilities. The child is not in school.
- Convertible strabismus, cataract. The fundus objective is advanced retinopathy pigmented both tubal vision, visual acuity lowered.
- At this stage: No disorders of carbohydrate metabolism. Renal ultrasound was normal, as well as serum creatinine

The 18-month-old sister presents:

- Obesity BMI: 25.5 size: 80 cm Weight: 17kg (Fig 1.D)
- post-axial polydactyly at both feet (Fig 1.E)
- Small lip hypoplasia
- The lack of acquisition of standing and walking
- No carbohydrate metabolism disorders or renal impairment detected at this stage



(A)



(C) (E) (E) Fig 1 :Some images representing patients with Bardet-Biedl syndrome.

Diagnosing BBS

- The diagnosis is based on the combination of four primary criteria, including at least one of the first two [1].
- Molecular confirmation of BBS has evolved over the last decade to nextgeneration sequencing gene panels containing all known BBS genes. The frequency at which molecular confirmation is achieved has increased accordingly from approximately 40–80% (Table 1). [2]

| | • |
|--|---------------|
| ii. Diagnostic features | |
| Primary features | Frequency |
| Rod-cone dystrophy | 93% |
| Polydactyly | 63-81% |
| All four limbs: | 21% |
| Upper limbs only: | 9% |
| Lower limbs only: | 21% |
| Obesity | 72-92% |
| Genital anomalies | 59-98% |
| Renal anomalies | 53% |
| Learning difficulties | 61% |
| Secondary features | |
| Speech delay | 54-81% |
| Developmental delay | 50-91% |
| Diabetes mellitus | 6-48% |
| Dental anomalies | 51% |
| Congenital heart disease | 7% |
| Brachydactyly/ syndactyly | 46-100%/8-95% |
| Ataxia/ poor coordination | 40-86% |
| Anosmia/hyposmia | 60% |
| and the second of the second o | |

| Gene name | |
|-------------------|--|
| | |
| | |
| 32 | |
| 2 | |
| | |
| 90 | |
| CP | |
| 4 <i>S</i> | |
| 1 | |
| | |
| , | |
| 2 | |
| 37 | |
| | |
| | |
| | |

Table1: Known genes causin BBs [3]

Up to 100% of

patients

Fig 2: Frequency of diagnostic features [3]

Pharmacological development process Clinical trial Pre-clinical studies FDA approved % BBS beneficiaries Intervention Up to 70% including Gene therapy BBS1 gene therapy RPE65 retinal dystrophy patients with BBS1 and BBS10 Exon skipping LCA, Usher Up to 9% of patients therapy Up to 11% of Read through PCD; Usher, RP patients therapy Up to 100% of Gene editing Dependent on the Targeted therapies Setmelanotide Dependent on the Drug repurposing

Future therapies for BBS

Fig 4: Future therapies for BBS [3]

Management and difficulties

| Fig 3: BBS requiring assessment [4] | | | | | |
|-------------------------------------|---|---|--|--|--|
| | • Weight • Blood pressure. • Renal, thyroid, liver function tests, glucose and lipid profile. • Ophthalmology review. • Endocrinology review. • ERG of patient >5 years old | At least once and more often if required Review by a clinical geneticist. DNA for molecular diagnostics. nephrology review . Renal USS Dietetics review Developmental and educational assessment. Hearing evaluation. Clinical psychology | Oral glucose tolerance test Referral to speech therapy Echocardiography/referral to cardiology Referral to mental health services Referral to orthodontist | | |
| | years old | Clinical psychology review | | | |

- A multidisciplinary approach is required to manage BBS. Although research is in progress, there still no targeted treatment for BBS.
- Complications associated should be treated symptomatically.
- Difficulty performing ophthalmological examinations visual fields, optical coherence tomography requiring patient cooperation due to age and intellectual deficit. Weight management is also a big challenge in front of learning difficulties.

References

- [1] Protocole National de Diagnostic et de Soins concernant le syndrome de Bardet Biedl, Haute autorité de santé 2019
- [2] Forsythe E, Beales PL. Bardet-Biedl syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, Stephens K, Amemiya A, Ledbetter N, editors., editors. GeneReviews(R). Seattle, WA: (2003).
- [3Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet-Biedl Syndrome-now and in the future. Front Pediatr. 2018;6:23.
- [4] Forsythe E, Beales PL. Bardet–Biedl syndrome. Eur J Hum Genet 2013;.





BBS pharmacogenomics panel

Pharmacogenomic